• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …

Background Aspirin is the only antiplatelet agent with a Class I recommendation for long-
term prevention of cardiovascular events in patients with coronary artery disease (CAD) …

Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …

Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …

Background: Long-term outcomes of antiplatelet monotherapy in patients who receive
percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal …

For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …